Clinical psychopharmacology of eating disorders: a research update

被引:49
|
作者
Hay, Phillipa J. [1 ,2 ]
Claudino, Angelica M. [3 ]
机构
[1] Univ Western Sydney, Sch Med, Penrith, NSW 1797, Australia
[2] James Cook Univ, Sch Med, Townsville, Qld, Australia
[3] Univ Fed Sao Paulo, Dept Psychiat, Eating Disorders Programme PROATA, Sao Paulo, Brazil
来源
关键词
Anorexia nervosa; binge eating; bulimia nervosa; treatments; PLACEBO-CONTROLLED TRIAL; COGNITIVE-BEHAVIORAL THERAPY; SHORT-TERM TREATMENT; ANOREXIA-NERVOSA; BULIMIA-NERVOSA; DOUBLE-BLIND; OPEN-LABEL; PHARMACOLOGICAL-TREATMENTS; ATYPICAL ANTIPSYCHOTICS; RESTRICTING-TYPE;
D O I
10.1017/S1461145711000460
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The paper presents a critical review (with search date 2010) of the major psychotropic medications assessed in eating disorders, namely antipsychotics, antidepressants, mood-stabilizing medications, anxiolytic and other agents. The evidence of efficacy of drug treatments is mostly weak or moderate. In addition, attrition rates are usually higher than for psychotherapies. However, there is support for use of antidepressants, particularly high-dose fluoxetine in bulimia nervosa, and anticonvulsants (topiramate) for binge-eating disorder. Low-dose antipsychotic medication may be clinically useful as adjunct treatment in acute anorexia, particularly where there is high anxiety and obsessive eating-related ruminations and failure to engage, but more trials are needed. Drug therapies such as topiramate and anti-obesity medication may aid weight loss in obese or overweight patients with binge-eating disorder; however, common or potentially serious adverse effects limit their use.
引用
收藏
页码:209 / 222
页数:14
相关论文
共 50 条